Patients Switching To Novo Nordisk's Wegovy Pill From Shots Lose More Weight In Real-World Study

Study participants lost an average of 4.1% of their body weight over three months after transitioning from injectable obesity therapies — including Wegovy and Lilly's Zepbound — to oral semaglutide, the active ingredient in Wegovy, ​as well as Ozempi ...Read more